CDC6 mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer.
10.3346/jkms.2018.33.e303
- Author:
Ye Hwan KIM
1
;
Young Joon BYUN
;
Won Tae KIM
;
Pildu JEONG
;
Chunri YAN
;
Ho Won KANG
;
Yong June KIM
;
Sang Cheol LEE
;
Sung Kwon MOON
;
Yung Hyun CHOI
;
Seok Joong YUN
;
Wun Jae KIM
Author Information
1. Department of Urology, Chungbuk National University, College of Medicine, Cheongju, Korea. wjkim@chungbuk.ac.kr
- Publication Type:Original Article
- Keywords:
Prostatic Neoplasms;
Gene Expression;
Immunohistochemical Staining;
CDC6
- MeSH:
Cell Cycle;
DNA Replication;
Gene Expression;
Humans;
Logistic Models;
Lymph Nodes;
Neoplasm Grading;
Neoplasm Metastasis;
Passive Cutaneous Anaphylaxis;
Prostate*;
Prostate-Specific Antigen;
Prostatic Hyperplasia;
Prostatic Neoplasms*;
Real-Time Polymerase Chain Reaction;
RNA, Messenger*
- From:Journal of Korean Medical Science
2018;33(47):e303-
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Cell division cycle 6 (CDC6) is an essential regulator of DNA replication and plays important roles in the activation and maintenance of the checkpoint mechanisms in the cell cycle. CDC6 has been associated with oncogenic activities in human cancers; however, the clinical significance of CDC6 in prostate cancer (PCa) remains unclear. Therefore, we investigated whether the CDC6 mRNA expression level is a diagnostic and prognostic marker in PCa. METHODS: The study subjects included 121 PCa patients and 66 age-matched benign prostatic hyperplasia (BPH) patients. CDC6 expression was evaluated using real-time polymerase chain reaction and immunohistochemical (IH) staining, and then compared according to the clinicopathological characteristics of PCa. RESULTS: CDC6 mRNA expression was significantly higher in PCa tissues than in BPH control tissues (P = 0.005). In addition, CDC6 expression was significantly higher in patients with elevated prostate-specific antigen (PSA) levels (> 20 ng/mL), a high Gleason score, and advanced stage than in those with low PSA levels, a low Gleason score, and earlier stage, respectively. Multivariate logistic regression analysis showed that high expression of CDC6 was significantly associated with advanced stage (≥ T3b) (odds ratio [OR], 3.005; confidence interval [CI], 1.212–7.450; P = 0.018) and metastasis (OR, 4.192; CI, 1.079–16.286; P = 0.038). Intense IH staining for CDC6 was significantly associated with a high Gleason score and advanced tumor stage including lymph node metastasis stage (linear-by-linear association, P = 0.044 and P = 0.003, respectively). CONCLUSION: CDC6 expression is associated with aggressive clinicopathological characteristics in PCa. CDC6 may be a potential diagnostic and prognostic marker in PCa patients.
